NASDAQ: KZIA - Kazia Therapeutics Limited

Yield per half year: +4.5%
Sector: Healthcare

Share chart Kazia Therapeutics Limited

Extended chart Simple chart
Financial Markets by TradingView

About

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0
EBITDA -0.0073
Число акций ао 0.18428 млрд
P/S 13748.76
P/BV 1.52
EV/EBITDA -2.2
Цена ао 0.4286
ISIN US48669G1058
Сайт https://www.kaziatherapeutics.com
Див.доход ао 53.19
Дивиденд ао 6.05
Валюта usd
IPO date 1999-01-06
Sector Health Care
Industry Biotechnology
Валюта отчета aud
Change price per day: +4.08% (0.4286)
Change price per week: +13.17% (0.3942)
Change price per month: +20.08% (0.3715)
Change price per 3 month: +132.34% (0.192)
Change price per half year: +4.5% (0.4269)
Change price per year: -53.04% (0.95)
Change price per 3 year: -96.17% (11.64)
Change price per 5 year: -81.17% (2.3696)
Change price per year to date: -33.42% (0.67)
All parameters

Underestimation

Title Value Grade
P/S 61225.34 1
P/BV 2.82 6
P/E 0 0
EV/EBITDA -1.37 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -72.87 0
ROE, % -169.83 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.75 7.5
Total: 2.5

Debt

Title Value Grade
Debt/EBITDA -0.0806 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -64.54 0
Yield Ebitda, % 205.33 10
Yield EPS, % 835.57 10
Total: 7.8
More

Institutions Volume Share, %
Armistice Capital, LLC 2475555 10.47
Platinum Investment Management Ltd 1821887 7.71
Morgan Stanley 201550 0.85
Bank of Montreal/Can/ 140166 0.59
HSBC Holdings PLC 100194 0.42
TWO SIGMA SECURITIES, LLC 58423 0.25
XTX Topco Ltd 19436 0.08
Acadian Asset Management. LLC 18682 0.08
Citadel Advisors Llc 12809 0.05
BNP Paribas Financial Markets 12700 0.05



Head Job title Payment Year of birth
Ms. Anna Sandham Company Secretary N/A
Dr. John Edwin Friend II, M.D. CEO, MD & Director 731.09k 1970 (54 years)
Ms. Gabrielle Heaton BBUS (ACC), CPA Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer 178.56k

Address: Australia, Sydney, Three International Towers - open in Google maps, open in Yandex maps
Website: https://www.kaziatherapeutics.com